About Us

ShunTech Biodevices aims to provide solutions to the clinical concerns of current eye stents through our advanced technology. We focus on biodevices of novel and new materials that are neither metal nor polymers. Inspired by the efforts of Dr. Larry Hench in the development of bioactive glass in 1969, we invented the Bioresorbable Glaucoma Scaffold (BGS) without indications of inflammatory response, scar tissue formation, biofilm or post-dissolution cytotoxic effects. Unlike devices composed of PLGA, our Bioresorbable Glaucoma Scaffolds (BGS) based on a dissolvable biosilicate material do not have encrusting erosions. The Bioresorbable Glaucoma Scaffold (BGS) mitigates infection, relieves chronic inflammation and promotes wound healing. With current MIG implants presenting many clinical challenges, ShunTech BGS strives to prevent implant rejection, enhance wound healing and act as a drug delivery system.